In our settings antibiotic prophylaxis has no significant effect on the incidence of SSI in elective repair of inguinal hernias with mesh. The most effective way to reduce the incidence of infection in prosthetic repair may be a specific center for treatment of abdominal wall hernias.
BACKGROUND:The incidence of pilonidal sinus may be increased in women with polycystic ovary syndrome.OBJECTIVE: This study aimed to compare the prevalence and risk factors of pilonidal sinus disease in women with and without polycystic ovary syndrome in the same population.DESIGN: This was a case-control study. SETTINGS:This study was conducted in a Turkish rural district state hospital. PATIENTS:This study included 40 female patients with polycystic ovary syndrome and 120 female patients without polycystic ovary syndrome. MAIN OUTCOME MEASURES:The prevalence of pilonidal sinus, age, BMI, number of baths per week, daily sitting time, and family history of pilonidal sinus were recorded. RESULTS:Pilonidal sinus was detected in 22.5% (12.5% asymptomatic pits, 10% symptomatic) of patients with polycystic ovary syndrome and 1.7% of the control group (p < 0.001). No difference was noted between the 2 groups in terms of BMI (p = 0.219). Family history was similar between the case and control groups (p = 0.520). No significant difference was noted between the 2 groups in terms of insufficient hygiene and daily sitting time (p = 0.763, p = 0.706). Multivariate analysis showed that the risk of pilonidal sinus was significantly higher in patients with a positive family history (p = 0.008). LIMITATIONS:The number of patients in the case and control groups in the study was limited. In addition, the control group may not fully reflect the general population because it was composed of only patients who presented to the general surgery and gynecology outpatient clinic for other reasons. The control group was not age matched. CONCLUSIONS:In our study, we found that the prevalence of pilonidal sinus was significantly higher in patients with polycystic ovary syndrome. See Video Abstract at http://links.lww.com/DCR/B945. ¿ES EL SÍNDROME DE OVARIO POLIQUÍSTICO UN FACTOR PREDISPONENTE PARA LA ENFERMEDAD DEL SENO PILONIDAL?ANTECEDENTES: La incidencia de enfermedad del seno pilonidal puede aumentar en mujeres con síndrome de ovario poliquístico.OBJETIVO: El objetivo fue comparar la prevalencia y los factores de riesgo de la enfermedad del seno pilonidal en una misma poblacion de mujeres con y sin síndrome de ovario poliquístico.DISEÑO: Este fue un estudio de casos y controles.ENTORNO CLÍNICO: Se llevó a cabo en un hospital estatal de un distrito rural turco.PACIENTES: Este estudio incluyó a 40 pacientes mujeres con síndrome de ovario poliquístico y 120 pacientes mujeres sin síndrome de ovario poliquístico. PRINCIPALES MEDIDAS DE VALORACIÓN:Se registraron la prevalencia del seno pilonidal, la edad, el IMC, el número de duchas por semana, el tiempo diario para sentarse y los antecedentes familiares de seno pilonidal.Funding/Support: None reported.
A AB BS S T TR RA AC CT T O Ob b j je ec c t ti i v ve e: : The sur gi cal in fec ti on ra te is not low in so me se ri es of elec ti ve pi lo ni dal sinus sur gery des pi te sing le do se an ti bi o tic proph yla xis. This study was de sig ned to com pa re wo und in fec ti on ra te after a sing le do se and a 5-day in tra ve no us course of cefazolin plus met ra ni da zo le admi nis tra ti on in patients who were operated employing Kary da kis flap for pi lo ni dal si nus. M Ma a t te e r ri i a al l a an nd d M Me et t h ho od ds s: : A to tal of 50 pa ti ents were in vol ved in this pros pec ti ve ran do mi sed cli ni cal study. Kary da kis flap pro ce du re was used and a va cu um dra in was left in si tu in all ca ses. The pa ti ents were di vi ded in to two gro ups: Gro up 1 had eit her a sing le do se of 500 mg met ra ni da zo le plus 500 mg ce fa zo lin so di um IV for proph yla xis and Gro up 2 were sub jec ted to sa me pre o pe ra ti ve drugs IV follo wed by the ir oral ad mi nis tra ti on for fi ve days (Se fa zol 500 mg tab let plus Flagyl 500 mg tab let, twice a day). The sur gi cal si te in fec ti on ra te, to tal dra i na ge vo lu me and dra in re mo val ti me we re re cor ded. R Re e s su ul lt ts s: : The study was trun ca ted be ca u se of oc cu ren ce of an unac cep tab le in fec ti on rate, thus, 30 pa ti ents we re ab le to con ti nu e on the study. Fi ve sur gi cal si te in fec ti ons we re ob ser ved in 14 pa ti ents in Gro up 1 (35.71%) whe re as only one in fec ti on was re cor ded in 16 pa ti ents in Group 2 (6.25%). Alt ho ugh the tar get pa ti ent num ber was not re ac hed, the sta tis ti cal dif fe ren ce was alre ady ac hi e ved (p= 0.04). The me an to tal dra i na ge vo lu me was gre a ter in Gro up 1 than in Gro up 2 (91.42 v.s. 72.12 ml; p= 0.073). Ho we ver, the me an dra in re mo val ti mes we re si mi lar. C Co on nc c l lu u s si i o on n: : The wo und in fec ti on ra te is high in elec ti ve pi lo ni dal si nus sur gery. Sing le do se proph ylac tic an tibi o tic com bi na ti on may not be suf fi ci ent to avo id wo und in fec ti on in pi lo ni dal si nus sur gery in which Kary da kis flap tech ni qu e is used. K Ke ey y W Wo or rd ds s: : Pi lo ni dal si nus; sur gi cal wo und infec ti on; an ti bi o tic proph yla xis; ce fa zo lin Ö ÖZ ZE ET T A Am ma aç ç: : Pi lo ni dal si nüs ne de niy le elek tif cer ra hi uy gu la nan ve tek doz an ti bi yo tik prof lak sisi ya pı lan ba zı se ri ler de cer ra hi alan en fek si yo nu ris ki dü şük de ğil dir. Bu ça lış ma da pi lo ni dal si nüs ta nı sıy la Kary da kis tek ni ğiy le ame li yat edi len has ta lar da tek doz se fa zo lin-met ra ni da zol prof lak sisi ile ay nı kom bi nas yo nun beş gün lük uy gu la ma sı nın ya ra en fek si yo nu ora nı na et ki si araş tı rıl dı. G Ge e r re eç ç v ve e Y Yö ön n t te em m l le er r: : Bu pros pek tif ran do mi ze ça lış ma ya top lam 50 has ta da hil edil me si plan lan dı. Tüm has ta la ra Kary da kis flep ame li ya tı ya pıl dı ve va kum lu dren kul la nıl dı. Has ta lar ay nı an t...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.